Achilles Therapeutics plc
ACHL · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | -0.01 | 0.03 | -0.04 |
| FCF Yield | 0.00% | -0.05% | -36.13% | -39.95% |
| EV / EBITDA | 2.02 | 3.51 | 4.40 | 4.99 |
| Quality | ||||
| ROIC | -18.93% | -14.71% | -10.51% | -13.67% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.06 | 1.43 | 0.76 | -0.06 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 99.90% | -27.46% | -1,509.53% |
| Safety | ||||
| Net Debt / EBITDA | 4.04 | 5.45 | 8.24 | 6.95 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -218.83 | -252.83 | -437.49 |